The authorized share increase is a major red flag for existing shareholders, as it enables significant future dilution. Traders should monitor the vote outcome and any subsequent equity offerings. The stock may face downward pressure as the market prices in potential dilution.
Price Chart
Executive Summary
Silo Pharma filed definitive additional proxy materials for its 2026 Annual Meeting, proposing a massive increase in authorized shares from 6,666,667 to 250,000,000 (a 37.5x expansion), along with director elections and auditor ratification. The authorized share increase is highly dilutive and signals potential future equity financing, which is bearish for existing shareholders given the company's $7M market cap.
Key Financial Metrics
Key Facts
- Proposal to increase authorized shares from 6,666,667 to 250,000,000 (37.5x increase)
- Annual Meeting scheduled for August 14, 2026; vote deadline August 13, 2026
- Board recommends 'For' all four proposals including the dilutive share authorization
- Market cap is approximately $7M, making the potential dilution severe
Financial Impact
Authorized share count increase from 6.67M to 250M, representing up to 37.5x potential dilution if all shares are issued
Risk Factors
- Massive dilution if authorized shares are issued
- Potential for future equity offerings at depressed prices
- Low market cap makes the company vulnerable to further dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-073368 |
| Document: 0001213900-26-073368-index-headers.html | 0001213900-26-073368 |
| Document: 0001213900-26-073368-index.html | 0001213900-26-073368 |
| Document: 0001213900-26-073368.txt | 0001213900-26-073368 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $1.20 | awaiting T+60 | awaiting T+60 | $1.29 (+7.50%) |
Oct 2, 2026 25d ago | 8-K | $1.49 | awaiting T+60 | awaiting T+60 | $1.29 (−13.42%) |
Sep 18, 2026 5w ago | Press Release | $1.84 | awaiting T+60 | awaiting T+60 | $1.29 (−29.89%) |
Aug 7, 2026 11w ago | EFFECT | $3.74 | awaiting T+60 | awaiting T+60 | $1.29 (−65.46%) |
Jul 14, 2026 15w ago | Press Release | $5.13 $1.44 | ▼ −71.93% | ▼ −75.31% | $1.29 (−74.85%) |
Jun 30, 2026 17w ago | DEFA14A | $6.21 $1.77 | ▲ +71.50% | ▲ +75.06% | $1.29 (+79.23%) |
Jun 3, 2026 20w ago | 8-K | $6.11 $2.54 | ▼ −58.43% | ▼ −60.31% | $1.29 (−78.89%) |
Jun 1, 2026 21w ago | 8-K | $4.99 $2.59 | ▼ −48.09% | ▼ −49.32% | $1.29 (−74.14%) |
Apr 29, 2026 25w ago | Press Release | $6.74 $4.47 | ▼ −33.63% | ▼ −37.74% | $1.29 (−80.85%) |
Apr 22, 2026 26w ago | Press Release | $7.11 $4.70 | ▼ −33.90% | ▼ −38.91% | $1.29 (−81.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers